

REMARKS

The first paragraph of the specification has been amended to update the priority claim by inserting the patent number of the now-issued parent patent.

Claims 20-31 are pending in this application. Claims 1-19 were cancelled without prejudice or disclaimer in the Preliminary Amendment filed March 30, 2004. New claim 32 is directed to a class of compounds and their pharmaceutically acceptable salts, as described throughout the originally-filed specification. For example, see page 36, lines 15-21 and originally-filed claim 8.

Claims 20-26 have been amended to clarify that the claims embrace pharmaceutically acceptable salts of the recited compounds. Support for these amendments is found throughout the originally-filed specification. For example, see page 192, line 37 to page 193, line 30.

Accordingly, no new matter has been added.


Prompt and favorable examination on the merits of the pending claims is respectfully solicited.

Respectfully submitted,

Date:

2 June 2005

By:



Joseph M. Skerpon
Registration No. 29,864

BANNER & WITCOFF, LTD.
1001 G Street, NW
Washington, DC 20001
202-824-3000